Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Nimotuzumab in Oral Squamous Cell Carcinoma
NCT05803915Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2023
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in oral squamous cell carcinoma (OSCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Major Pathologic Response rate at 18 months. Planned start May 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT05803915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803915.